Emalex Biosciences is developing innovative treatments for central nervous system (CNS) disorders. Their primary areas of research focus are on Restless Leg Syndrome and Tourette syndrome, a neurological condition characterized by involuntary tics. Emalex Biosciences' lead product, ecopipam, is a novel D1 receptor antagonist currently in late-stage development. Ecopipam has shown promising results in clinical trials for the treatment of Tourette syndrome, demonstrating significant reductions in tic severity. By addressing the underlying causes of Tourette syndrome, Emalex Biosciences aims to improve the quality of life for patients living with this debilitating condition.

Emalex Biosciences

Founded: 2018
Location: Chicago, Illinois
Employee range: 1-50
Clinical stage: Clin3 (fast track)
Therapy area: Tourette syndrome (ODD)
Drug types: NEU, PED
Lead product: Ecopipam (EBS-101)
Funding: 100 - 500M

Drug notes:

About:

Jobs: